FI3981437T3 - Nukleiinihapporokotteita - Google Patents
Nukleiinihapporokotteita Download PDFInfo
- Publication number
- FI3981437T3 FI3981437T3 FIEP21191353.8T FI21191353T FI3981437T3 FI 3981437 T3 FI3981437 T3 FI 3981437T3 FI 21191353 T FI21191353 T FI 21191353T FI 3981437 T3 FI3981437 T3 FI 3981437T3
- Authority
- FI
- Finland
- Prior art keywords
- virus
- vaccine
- human
- infection
- cationic lipid
- Prior art date
Links
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title claims 3
- 229940023146 nucleic acid vaccine Drugs 0.000 title claims 3
- 229960005486 vaccine Drugs 0.000 claims 13
- -1 cationic lipid Chemical class 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 238000007385 chemical modification Methods 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 1
- JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 claims 1
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims 1
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims 1
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 claims 1
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 claims 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 claims 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 claims 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 claims 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 claims 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 206010060931 Adenovirus infection Diseases 0.000 claims 1
- 241001302512 Banna virus Species 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241000702669 Coltivirus Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 241000190708 Guanarito mammarenavirus Species 0.000 claims 1
- 206010069767 H1N1 influenza Diseases 0.000 claims 1
- 241000893570 Hendra henipavirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241001479210 Human astrovirus Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000046923 Human bocavirus Species 0.000 claims 1
- 241001207270 Human enterovirus Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000342334 Human metapneumovirus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241000702617 Human parvovirus B19 Species 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000712890 Junin mammarenavirus Species 0.000 claims 1
- 241000712902 Lassa mammarenavirus Species 0.000 claims 1
- 241000712898 Machupo mammarenavirus Species 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000526636 Nipah henipavirus Species 0.000 claims 1
- 241000714209 Norwalk virus Species 0.000 claims 1
- 241000702259 Orbivirus Species 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 229930185560 Pseudouridine Natural products 0.000 claims 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000192617 Sabia mammarenavirus Species 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983250P | 2014-04-23 | 2014-04-23 | |
| US201462088994P | 2014-12-08 | 2014-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3981437T3 true FI3981437T3 (fi) | 2025-01-10 |
Family
ID=54333225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21191353.8T FI3981437T3 (fi) | 2014-04-23 | 2015-04-23 | Nukleiinihapporokotteita |
| FIEP21195046.4T FI4023249T3 (fi) | 2014-04-23 | 2015-04-23 | Nukleiinihapporokotteita |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21195046.4T FI4023249T3 (fi) | 2014-04-23 | 2015-04-23 | Nukleiinihapporokotteita |
Country Status (22)
| Country | Link |
|---|---|
| US (11) | US10022435B2 (enExample) |
| EP (4) | EP3981437B1 (enExample) |
| JP (3) | JP6881813B2 (enExample) |
| CN (1) | CN106659803A (enExample) |
| AU (3) | AU2015249553B2 (enExample) |
| CA (2) | CA2946751A1 (enExample) |
| CY (1) | CY1125084T1 (enExample) |
| DK (3) | DK4023249T3 (enExample) |
| ES (3) | ES3003986T3 (enExample) |
| FI (2) | FI3981437T3 (enExample) |
| HR (3) | HRP20241732T1 (enExample) |
| HU (3) | HUE069802T2 (enExample) |
| LT (3) | LT3134131T (enExample) |
| MA (2) | MA58292B1 (enExample) |
| PL (3) | PL4023249T3 (enExample) |
| PT (3) | PT3134131T (enExample) |
| RS (3) | RS66380B1 (enExample) |
| RU (2) | RU2021109685A (enExample) |
| SG (2) | SG11201608798YA (enExample) |
| SI (3) | SI3981437T1 (enExample) |
| SM (3) | SMT202500052T1 (enExample) |
| WO (1) | WO2015164674A1 (enExample) |
Families Citing this family (313)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP3417874B1 (en) | 2012-11-28 | 2024-09-11 | BioNTech SE | Individualized vaccines for cancer |
| BR112015022855A2 (pt) | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
| JP6586075B2 (ja) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| RS57739B1 (sr) | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| CN105431527A (zh) * | 2013-06-11 | 2016-03-23 | 比奥卡尔齐斯股份有限公司 | 用于长期储存的生物分子干燥方法 |
| CA2917348A1 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) * | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| AU2014340149B2 (en) | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| CN106413811A (zh) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | 精氨基琥珀酸合成酶缺乏症的mrna疗法 |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| AU2016253972B2 (en) * | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US20190008887A1 (en) * | 2015-07-30 | 2019-01-10 | ModernaTX Inc. | Multimeric mrna |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP3350333B2 (en) | 2015-09-17 | 2025-08-06 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
| WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| JP6997704B2 (ja) | 2015-10-14 | 2022-02-04 | トランスレイト バイオ， インコーポレイテッド | 生産性向上のためのｒｎａ関連酵素の修飾 |
| JP7384512B2 (ja) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| EP3365009A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| CN108699561B (zh) * | 2015-11-19 | 2022-09-13 | 创嘉生物科技有限公司 | 重组乳酸菌及其在口服通用流感疫苗中的用途 |
| PL3386484T3 (pl) * | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US11246920B2 (en) | 2016-03-03 | 2022-02-15 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| EP3825400B1 (en) | 2016-04-08 | 2024-12-25 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
| CN109640959B (zh) | 2016-04-29 | 2023-03-17 | 西奈山伊坎医学院 | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US12508308B2 (en) * | 2016-05-04 | 2025-12-30 | CureVac SE | Influenza mRNA vaccines |
| WO2017201328A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
| JP7194594B2 (ja) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| SI3458083T1 (sl) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| EP3469074B1 (en) | 2016-06-13 | 2020-12-09 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
| CN109789092A (zh) * | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| CN118108847A (zh) * | 2016-08-07 | 2024-05-31 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| IL308824A (en) * | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of administration thereof |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| WO2018067580A1 (en) | 2016-10-03 | 2018-04-12 | Duke University | Methods to identify immunogens by targeting improbable mutations |
| WO2018075830A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| CN110402145A (zh) * | 2016-10-26 | 2019-11-01 | 莫得纳特斯公司 | 用于增强免疫应答的信使核糖核酸及其使用方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CA3040337A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| US20190274968A1 (en) * | 2016-10-27 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018107088A2 (en) * | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| CA3049991A1 (en) | 2017-01-11 | 2018-07-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an immune response against zika virus |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| US20190351040A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Rna cancer vaccines |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| WO2018170256A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595676A4 (en) * | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CN107300583A (zh) * | 2017-04-18 | 2017-10-27 | 武汉博沃生物科技有限公司 | 疫苗中蔗糖含量的检测方法及其应用 |
| WO2018200737A1 (en) * | 2017-04-26 | 2018-11-01 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11596679B2 (en) | 2017-04-27 | 2023-03-07 | Vanderbilt University | Hepatitis C virus gene sequences and methods of use therefor |
| CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| AU2018275790B2 (en) * | 2017-06-02 | 2024-05-09 | Matthew Kerner | Genetically attenuated nucleic acid vaccine |
| AU2018275267B2 (en) | 2017-06-02 | 2024-10-10 | Matthew Kerner | Phenotypically wild-type and genetically attenuated viruses |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP4501322A3 (en) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| US20200254086A1 (en) * | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| JP7385556B2 (ja) | 2017-09-01 | 2023-11-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| WO2019067910A1 (en) * | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION |
| WO2019070730A1 (en) | 2017-10-02 | 2019-04-11 | Duke University | MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES |
| US20220233568A1 (en) * | 2017-10-19 | 2022-07-28 | Curevac Ag | Novel artificial nucleic acid molecules |
| GB201718660D0 (en) * | 2017-11-10 | 2017-12-27 | Ucl Business Plc | Improved liposome for mRNA delivery to cells |
| MA50813A (fr) * | 2017-11-21 | 2020-09-30 | Modernatx Inc | Vaccins contre le virus d'epstein-barr |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| CN111819185A (zh) | 2017-12-15 | 2020-10-23 | 旗舰创业创新第六有限责任公司 | 包含环状多核糖核苷酸的组合物及其用途 |
| US11167043B2 (en) | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
| CN111712468A (zh) | 2017-12-22 | 2020-09-25 | 北卡罗莱纳州立大学 | 聚合物荧光团、包含其的组合物及制备和使用其的方法 |
| WO2019135701A1 (en) | 2018-01-05 | 2019-07-11 | Nilsson Rolf Jonas Andreas | Endogenous tumor-derived circular rna and proteins thereof for use as vaccine |
| CN120310791A (zh) | 2018-01-12 | 2025-07-15 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
| SG11202006528XA (en) | 2018-01-12 | 2020-08-28 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| EP3746090A4 (en) * | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| US11633467B2 (en) | 2018-02-15 | 2023-04-25 | Icon Genetics Gmbh | Immunogenic composition and vaccine for generating an immune response to norovirus |
| CN108424881B (zh) * | 2018-03-23 | 2021-07-27 | 中国食品药品检定研究院 | 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用 |
| TWI682779B (zh) * | 2018-04-03 | 2020-01-21 | 林淑卿 | 豬疾病疫苗用佐劑及其製備方法 |
| CN108324941A (zh) * | 2018-04-03 | 2018-07-27 | 林淑卿 | 猪疾病疫苗用佐剂及其制备方法 |
| US11679159B2 (en) * | 2018-04-29 | 2023-06-20 | Precision NanoSystems ULC | Compositions for transfecting resistant cell types |
| US11964051B2 (en) * | 2018-05-16 | 2024-04-23 | Translate Bio, Inc. | Ribose cationic lipids |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| CN112399860B (zh) | 2018-06-06 | 2024-08-16 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| WO2020051223A1 (en) | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| CN112805238A (zh) | 2018-07-03 | 2021-05-14 | 芬内克制药股份有限公司 | 无水硫代硫酸钠和其调配物 |
| KR102950141B1 (ko) | 2018-08-24 | 2026-04-07 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 정제 방법 |
| EP3846857A4 (en) * | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| EP3856757A4 (en) | 2018-09-28 | 2022-06-29 | Nutcracker Therapeutics, Inc. | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
| US20210379178A1 (en) * | 2018-10-01 | 2021-12-09 | Duke University | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
| EP3860650A4 (en) | 2018-10-01 | 2022-06-29 | Duke University | Hiv-1 envelope stabilizing mutations |
| HRP20240586T1 (hr) * | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| WO2020106946A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| US12042527B2 (en) | 2019-01-08 | 2024-07-23 | Modernatx, Inc. | Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| PT3908568T (pt) | 2019-01-11 | 2024-09-30 | Acuitas Therapeutics Inc | Lípidos para a administração de agentes ativos por nanopartículas lipídicas |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| EP3941938A1 (en) | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| WO2020198403A2 (en) | 2019-03-25 | 2020-10-01 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
| CN109880835B (zh) * | 2019-03-28 | 2022-03-25 | 扬州大学 | 重组h9n2禽流感病毒株、其制备方法、禽流感疫苗及其应用 |
| CN114040782A (zh) * | 2019-04-30 | 2022-02-11 | 威斯康星州医药大学股份有限公司 | 跨鼓膜递送平台及其用途 |
| BR112021023411A2 (pt) | 2019-05-22 | 2022-02-01 | Massachusetts Inst Technology | Composições e métodos de rna circular |
| AU2020298267A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Self-replicating RNA molecules for hepatitis B virus (HBV) vaccines and uses thereof |
| WO2021050986A1 (en) * | 2019-09-11 | 2021-03-18 | Modernatx, Inc. | Lnp-formulated mrna therapeutics and use thereof for treating human subjects |
| EP4031662A1 (en) | 2019-09-20 | 2022-07-27 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| CN110897032B (zh) * | 2019-11-19 | 2025-10-14 | 华南理工大学 | 一种发酵饲料蛋白及其制备方法与应用 |
| CN121422256A (zh) | 2019-12-04 | 2026-01-30 | 奥纳治疗公司 | 环状rna组合物和方法 |
| WO2021118976A1 (en) | 2019-12-09 | 2021-06-17 | University Of Georgia Research Foundation, Inc. | M. tuberculosis ag85 proteins and methods of use |
| US20230062603A1 (en) * | 2020-01-07 | 2023-03-02 | Translate Bio Ma, Inc. | Formulations for delivery of oligonucleotides to lung cells |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| BR112022015565A2 (pt) * | 2020-02-07 | 2022-09-27 | Modernatx Inc | Vacinas de domínio de mrna para sars-cov-2 |
| CA3167611A1 (en) | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| MX2022009943A (es) * | 2020-02-14 | 2022-10-18 | Etherna Immunotherapies Nv | Vacunas intranasales de arnm. |
| CN111378785A (zh) * | 2020-03-12 | 2020-07-07 | 仁宽(上海)生物科技有限公司 | 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用 |
| KR20220156933A (ko) | 2020-03-23 | 2022-11-28 | 에이치디티 바이오 코포레이션 | Rna의 전달을 위한 조성물 및 방법 |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| WO2021229448A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Rna replicon encoding a stabilized corona virus spike protein |
| CN111647557A (zh) * | 2020-05-18 | 2020-09-11 | 中国人民解放军第四军医大学 | 一种表面偶联s蛋白的外泌体及其制备方法和应用 |
| CN113679701B (zh) * | 2020-05-18 | 2024-04-30 | 中国科学院上海药物研究所 | 邻苯三酚及其衍生物作为共价配体反应弹头的用途 |
| WO2021236855A1 (en) * | 2020-05-19 | 2021-11-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| IL298362A (en) * | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus antigen compositions and their uses |
| CA3170740A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| TWI907439B (zh) * | 2020-06-11 | 2025-12-11 | 日商第一三共股份有限公司 | 核酸脂質粒子疫苗 |
| CN111714621B (zh) * | 2020-06-29 | 2021-04-27 | 中国科学院昆明动物研究所 | 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用 |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4179112A4 (en) | 2020-07-13 | 2024-11-20 | The Board of Trustees of the Leland Stanford Junior University | Systems and methods to assess rna stability |
| ES3054438T3 (en) | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| US12605239B2 (en) | 2020-07-29 | 2026-04-21 | North Carolina State University | Enhancement of hydration and improvement in gut health through cloacal delivery of products |
| MX2023001187A (es) * | 2020-07-31 | 2023-04-04 | Combined Therapeutics Inc | Composiciones y métodos para una vacunación mejorada. |
| WO2022031376A1 (en) * | 2020-08-03 | 2022-02-10 | Avalon GloboCare Corp. | Emulsomes comprising s-layer fusion proteins and methods of use thereof |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4204015A4 (en) | 2020-08-31 | 2025-01-01 | The Board of Trustees of the Leland Stanford Junior University | Systems and methods for producing rna constructs with increased translation and stability |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4228658A4 (en) | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| WO2022091119A1 (en) * | 2020-10-26 | 2022-05-05 | Gunjan Kumar | A pharmaceutical kit comprising copper sulfate and ascorbic acid |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| CN112358545B (zh) * | 2020-11-10 | 2022-03-01 | 中国农业大学 | 鸽毛滴虫与白色念珠菌二联卵黄抗体粉的制备方法及应用 |
| US20220175690A1 (en) * | 2020-11-17 | 2022-06-09 | Phosphorex, Inc. | Novel drug delivery composition and process for blood-brain barrier crossing |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| GB202019916D0 (en) * | 2020-12-16 | 2021-01-27 | Imperial College Innovations Ltd | RNA vaccine |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| US12263217B2 (en) | 2020-12-23 | 2025-04-01 | Daykin Molecular Systems, LLC | Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport |
| EP4274607A1 (en) * | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| US20240066119A1 (en) * | 2021-01-13 | 2024-02-29 | University Of Maryland, College Park | Methods and platforms for eliciting an immune response in the treatment of cancer and compositions and vaccines relating thereto |
| WO2022155524A1 (en) * | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240165045A1 (en) * | 2021-03-08 | 2024-05-23 | Board Of Regents, The University Of Texas System | Dry powder formulations of nucleic acid lipid nanoparticles |
| AU2022239614A1 (en) | 2021-03-19 | 2023-10-12 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
| US11260113B1 (en) | 2021-03-26 | 2022-03-01 | King Abdulaziz University | NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US20240336672A1 (en) | 2021-04-26 | 2024-10-10 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| JPWO2022244801A1 (enExample) | 2021-05-19 | 2022-11-24 | ||
| KR20240009952A (ko) | 2021-05-19 | 2024-01-23 | 다이이찌 산쿄 가부시키가이샤 | 인플루엔자 바이러스 핵산 지질 입자 백신 |
| GB202108444D0 (en) * | 2021-06-14 | 2021-07-28 | Imperial College Innovations Ltd | Sub-micron particle |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN113476598A (zh) * | 2021-07-20 | 2021-10-08 | 武汉圣润生物科技有限公司 | 一种新型冠状病毒亚蛋白纳米疫苗及其制备方法和应用 |
| US12251471B2 (en) | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| WO2023008881A1 (ko) * | 2021-07-29 | 2023-02-02 | 주식회사 에스엠엘바이오팜 | 발현 시스템 및 이를 포함하는 핵산 기반 약학 조성물 |
| EP4387596A1 (en) * | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| US20240350410A1 (en) * | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| WO2023048760A1 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| CA3232719A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Sars-cov-2 rna vaccine compositions and methods of use |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| JP2024536360A (ja) * | 2021-10-06 | 2024-10-04 | セキラス インコーポレイテッド | 核酸結合タンパク質を含む脂質ナノ粒子 |
| IL311855A (en) * | 2021-10-08 | 2024-05-01 | Pfizer | Immunogenic lnp compositions and methods thereof |
| WO2023064469A1 (en) | 2021-10-13 | 2023-04-20 | Modernatx, Inc. | Compositions of mrna-encoded il15 fusion proteins and methods of use thereof |
| US20250295755A1 (en) | 2021-10-22 | 2025-09-25 | Sail Biomedicines, Inc. | Mrna vaccine composition |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| CA3238764A1 (en) | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023104904A2 (en) | 2021-12-08 | 2023-06-15 | Genclis | The sars-cov-2 and variants use two independent cell receptors to replicate |
| CN115813848B (zh) * | 2021-12-10 | 2023-08-08 | 上海臻上医药科技有限公司 | 微针注射mRNA编码双特异性抗体药物的试剂、方法和应用 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2023118979A1 (en) * | 2021-12-22 | 2023-06-29 | Novo Integrated Sciences Inc. | System and method for antibody activators in an aqueous iodine solution |
| EP4460326A4 (en) * | 2022-01-07 | 2026-03-11 | Hdt Bio Corp | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIVALENT IMMUNE RESPONSES |
| CN114437237B (zh) * | 2022-01-12 | 2023-10-24 | 黑龙江八一农垦大学 | 金黄色葡萄球菌trap靶向重组蛋白抗原及其用途 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN115304756B (zh) * | 2022-01-30 | 2023-05-09 | 上海科技大学 | 一种五元脂质纳米颗粒及其制备方法和应用 |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023198828A1 (en) | 2022-04-13 | 2023-10-19 | Universitat Autònoma De Barcelona | Treatment of neuromuscular diseases via gene therapy that expresses klotho protein |
| WO2023212696A1 (en) | 2022-04-29 | 2023-11-02 | Modernatx, Inc. | Lyophilized human cytomegalovirus vaccines |
| CN116942610A (zh) * | 2022-04-29 | 2023-10-27 | 北京祥瑞生物制品股份有限公司 | 一种核酸药物递送系统及其制备方法 |
| CN114591386B (zh) * | 2022-05-10 | 2022-09-09 | 深圳厚存纳米药业有限公司 | 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| EP4296274A1 (en) | 2022-06-23 | 2023-12-27 | Universidade de Santiago de Compostela | Peptides for intracellular delivery |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024020453A2 (en) * | 2022-07-20 | 2024-01-25 | Hdt Bio Corp. | Immune system modulators and uses thereof |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| GB202216449D0 (en) | 2022-11-04 | 2022-12-21 | Io Biotech Aps | TGF-BETA1 vaccine |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| AU2023414262B2 (en) | 2022-12-29 | 2025-08-14 | Rinuagene Biotechnology Co., Ltd. | Polynucleotide molecule for preventing or treating hpv infection-related diseases |
| CN121057577A (zh) | 2023-01-27 | 2025-12-02 | 赛欧生物医药股份有限公司 | 经修饰的脂质组合物及其用途 |
| EP4410316A1 (en) * | 2023-02-01 | 2024-08-07 | 4basebio UK Ltd | Nanoparticles for delivery of nucleic acid cargos |
| WO2024178305A1 (en) | 2023-02-24 | 2024-08-29 | Modernatx, Inc. | Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| AU2024234874A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| WO2024238881A1 (en) * | 2023-05-17 | 2024-11-21 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating candida auris infection |
| WO2024254518A2 (en) * | 2023-06-07 | 2024-12-12 | Nvelop Therapeutics, Inc. | Compositions of lipid delivery particles and method of use thereof |
| WO2025006263A2 (en) * | 2023-06-27 | 2025-01-02 | Cz Biohub Sf, Llc | Design of universal influenza vaccine candidates via antigen reorientation |
| WO2025007148A1 (en) * | 2023-06-30 | 2025-01-02 | Orna Therapeutics, Inc. | Polymer lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2025027116A1 (en) | 2023-08-01 | 2025-02-06 | Institut Curie | Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025054360A1 (en) * | 2023-09-05 | 2025-03-13 | The Regents Of The University Of California | Injectable hydrogel for sustained co-delivery of an antigen and an adjuvant, and uses thereof |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| AU2024357861A1 (en) | 2023-10-12 | 2026-04-23 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025153707A1 (en) | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
| WO2025219454A1 (en) | 2024-04-18 | 2025-10-23 | Poltreg S.A. | Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes |
| WO2025231407A1 (en) * | 2024-05-03 | 2025-11-06 | Nutech Ventures | Lipid nanoparticles and methods of making and using |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| WO2026019998A1 (en) * | 2024-07-19 | 2026-01-22 | The Cleveland Clinic Foundation | Vaccines for kaposi's sarcoma-associated herpesvirus |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| CN119424376B (zh) * | 2025-01-13 | 2025-07-25 | 北京大学 | 一种可超声靶向的脂质纳米颗粒及其应用 |
Family Cites Families (482)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0204401A1 (en) | 1985-04-09 | 1986-12-10 | Biogen, Inc. | Method of improving the yield of polypeptides produced in a host cell by stabilizing mRNA |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| FR2676072B1 (fr) | 1991-05-03 | 1994-11-18 | Transgene Sa | Vecteur de delivrance d'arn. |
| US6355247B1 (en) | 1994-06-02 | 2002-03-12 | Chiron Corporation | Nucleic acid immunization using a virus-based infection/transfection system |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| US6111095A (en) | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| CA2258568A1 (en) | 1996-06-21 | 1997-12-24 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| US5939262A (en) | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US5989911A (en) | 1997-05-09 | 1999-11-23 | University Of Massachusetts | Site-specific synthesis of pseudouridine in RNA |
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| EP1021548A1 (en) | 1997-10-07 | 2000-07-26 | University Of Maryland Biotechnology Institute | Method for introducing and expressing rna in animal cells |
| US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
| US20090148906A1 (en) | 1998-09-29 | 2009-06-11 | Shire Human Genetic Therapies, Inc. A Delaware Corporation | Optimized messenger rna |
| WO2000050586A2 (en) | 1999-02-22 | 2000-08-31 | European Molecular Biology Laboratory | In vitro translation system |
| WO2000029561A2 (en) | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
| ES2238799T3 (es) | 1999-09-09 | 2005-09-01 | Curevac Gmbh | Transferencia de arn-m. |
| WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
| AU7725500A (en) | 1999-09-30 | 2001-04-30 | National Jewish Medical And Research Center | Method for inhibition of pathogenic microorganisms |
| AU2001275423B2 (en) | 2000-06-09 | 2007-01-11 | Regulon, Inc. | Encapsulation of polynucleotides and drugs into targeted liposomes |
| GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
| US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| JP2004535765A (ja) | 2000-12-07 | 2004-12-02 | カイロン コーポレイション | 前立腺癌においてアップレギュレートされた内因性レトロウイルス |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| ES2295351T3 (es) | 2001-04-21 | 2008-04-16 | Curevac Gmbh | Dispositivo para la inyeccion de rnam. |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| WO2003059381A2 (en) | 2002-01-18 | 2003-07-24 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| AU2003249208B2 (en) | 2002-07-16 | 2010-03-04 | Vgx Pharmaceuticals, Llc | Codon optimized synthetic plasmids |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| WO2005034992A2 (en) | 2003-09-15 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv vaccines based on env of multiple clades of hif |
| TW200515917A (en) | 2003-09-15 | 2005-05-16 | Us Government | Methods and compositions for the generation of a protective immune response against SARS-COV |
| US20050065114A1 (en) | 2003-09-23 | 2005-03-24 | Jean-Claude Yvin | Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| JP5331340B2 (ja) * | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| AU2005274948B2 (en) | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| US8663599B1 (en) | 2004-10-05 | 2014-03-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| EP1846443A4 (en) | 2005-01-07 | 2008-07-23 | Glaxo Group Ltd | NEW USE |
| US7566454B2 (en) | 2005-02-24 | 2009-07-28 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US20120021042A1 (en) | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| US8603457B2 (en) | 2005-12-02 | 2013-12-10 | University Of Rochester | Nonsense suppression and genetic codon alteration by targeted modification |
| CA2631714C (en) | 2005-12-02 | 2014-09-16 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| EP2026839A4 (en) | 2005-12-14 | 2009-04-01 | Univ Oklahoma | RNA VIRUS VACCINE AND METHODS |
| ES2374458T3 (es) | 2006-01-13 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Vacunas y agentes inmunoterapéuticos que utilizan il-15 optimizada en codones, y métodos para utilización de los mismos. |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| EP2295045A1 (en) | 2006-07-07 | 2011-03-16 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
| CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| CN104140958A (zh) * | 2006-08-09 | 2014-11-12 | 米迪缪尼有限公司 | 流感血凝素和神经氨酸酶变体 |
| EP2450377A1 (en) | 2006-09-07 | 2012-05-09 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| WO2008143640A1 (en) * | 2006-11-07 | 2008-11-27 | Government Of The United Nations Of America, As Represented By The Secretariat, Department Of Healthand Human Services | Influenza virus nucleic acid microarray and method of use |
| PT2121011E (pt) | 2006-12-06 | 2014-07-31 | Novartis Ag | Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe |
| WO2008140615A2 (en) | 2006-12-21 | 2008-11-20 | Novozymes, Inc. | Modified messenger rna stabilizing sequences for expressing genes in bacterial cells |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| US8057804B2 (en) | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| EP2450368A1 (en) | 2007-01-30 | 2012-05-09 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2008109712A2 (en) | 2007-03-05 | 2008-09-12 | Washington University | Nanoparticle delivery systems for membrane-integrating peptides |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| US7682789B2 (en) | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
| EP2160464B1 (en) | 2007-05-30 | 2014-05-21 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| EP2160198A2 (en) | 2007-05-31 | 2010-03-10 | Statens Serum Institut | Influenza vaccines |
| US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| US20110086904A1 (en) | 2007-09-17 | 2011-04-14 | The Trustees Of The University Of Pennsylvania | GENERATION OF HYPERSTABLE mRNAs |
| EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| WO2009046388A1 (en) | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| WO2009062348A1 (en) | 2007-11-14 | 2009-05-22 | Institute Of Microbiology, Chinese Academy Of Sciences | Methods for inhibiting influenza virus infection and their drugs |
| US8081186B2 (en) | 2007-11-16 | 2011-12-20 | Microsoft Corporation | Spatial exploration field of view preview mechanism |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| US20120027813A1 (en) | 2008-02-22 | 2012-02-02 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines for pediatric use |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| JP5586064B2 (ja) * | 2008-03-28 | 2014-09-10 | 国立大学法人北海道大学 | 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体 |
| CA2721333C (en) * | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| JP5781929B2 (ja) | 2008-07-15 | 2015-09-24 | ノバルティス アーゲー | 免疫原性の両親媒性ペプチド組成物 |
| WO2010009065A2 (en) | 2008-07-15 | 2010-01-21 | Novartis Ag | Amphipathic peptide compositions |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| AU2015210364B2 (en) | 2008-10-09 | 2017-03-09 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| JP2012505913A (ja) | 2008-10-16 | 2012-03-08 | マリーナ バイオテック，インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| EP2358386B1 (en) | 2008-11-28 | 2016-11-02 | Statens Serum Institut | Optimized influenza vaccines |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| KR20110126717A (ko) | 2009-02-24 | 2011-11-23 | 더 스크립스 리서치 인스티튜트 | 단백질 생성 증강을 위한 ｍｒｎａ １차 구조의 재구조화 |
| US8460696B2 (en) | 2009-03-20 | 2013-06-11 | Egen, Inc. | Polyamine derivatives |
| WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| JP5894913B2 (ja) * | 2009-06-15 | 2016-03-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ |
| WO2010148085A1 (en) | 2009-06-16 | 2010-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rna nanoparticles and methods of use |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| CA2769670C (en) | 2009-07-31 | 2018-10-02 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2011017548A1 (en) | 2009-08-05 | 2011-02-10 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| ES2641892T3 (es) | 2009-08-26 | 2017-11-14 | Selecta Biosciences, Inc. | Composiciones que inducen la ayuda de las células T |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| US8808982B2 (en) | 2009-12-07 | 2014-08-19 | Cellscript, Llc | Compositions and methods for reprogramming eukaryotic cells |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US20110184160A1 (en) | 2010-01-26 | 2011-07-28 | Weiner David B | Nucleic acid molecule encoding consensus influenza a hemagglutinin h1 |
| WO2011106607A2 (en) | 2010-02-26 | 2011-09-01 | Juvaris Biotherapeutics, Inc. | Subunit vaccines for herpes viruses and methods of use |
| US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| US20130037977A1 (en) * | 2010-04-08 | 2013-02-14 | Paul A. Burke | Preparation of Lipid Nanoparticles |
| US8802438B2 (en) | 2010-04-16 | 2014-08-12 | Children's Medical Center Corporation | Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs |
| US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| MX342608B (es) | 2010-07-06 | 2016-10-06 | Novartis Ag * | Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion. |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012023044A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| WO2012024621A2 (en) | 2010-08-20 | 2012-02-23 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin |
| JP2013538211A (ja) | 2010-08-23 | 2013-10-10 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗原に対する免疫反応を誘発する標的マルチエピトープ剤形 |
| SI4043040T1 (sl) * | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| JP2013541510A (ja) | 2010-08-31 | 2013-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法 |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| MX2013002332A (es) | 2010-08-31 | 2013-03-18 | Novartis Ag | Lipidos apropiados para suministro liposomal del arn que codifica la proteina. |
| CA2809858C (en) | 2010-09-20 | 2019-11-12 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| CA2811430A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012051211A2 (en) | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| JP6077450B2 (ja) | 2010-11-12 | 2017-02-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| EP2640426B1 (en) | 2010-11-16 | 2016-02-03 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotides |
| WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| US20120177701A1 (en) | 2010-12-31 | 2012-07-12 | Selecta Biosciences, Inc. | Compositions comprising immunostimulatory nucleic acids and related methods |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
| US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
| WO2012116715A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP3460064B8 (en) | 2011-04-03 | 2024-03-20 | The General Hospital Corporation d/b/a Massachusetts General Hospital | Efficient protein expression in vivo using modified rna (mod-rna) |
| JP2014518620A (ja) | 2011-04-26 | 2014-08-07 | モレキュラー エクスプレス，インコーポレイテッド | リポソーム製剤 |
| AU2012249474A1 (en) | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| CA2835428A1 (en) | 2011-05-17 | 2012-11-22 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof for non-human vertebrates |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| EP2714017B1 (en) | 2011-06-02 | 2018-08-01 | The Regents of The University of California | Membrane encapsulated nanoparticles and method of use |
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
| US9580475B2 (en) | 2011-06-20 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US9008142B2 (en) | 2011-07-22 | 2015-04-14 | Insight Photonic Solutions, Inc. | System and method for optimization of coherence length of tunable laser sources |
| US9018089B2 (en) | 2011-08-30 | 2015-04-28 | International Business Machines Corporation | Multiple step anneal method and semiconductor formed by multiple step anneal |
| MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| CA3185394A1 (en) | 2011-09-02 | 2013-03-07 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
| EP4241785B1 (en) * | 2011-09-20 | 2026-01-28 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| EP2758038B1 (en) | 2011-09-23 | 2018-05-30 | The United States of America, as represented by The Secretary, Department of Health & Human Services | Novel influenza hemagglutinin protein-based vaccines |
| EP3456317B1 (en) | 2011-09-27 | 2025-09-24 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| RU2014118727A (ru) | 2011-10-11 | 2015-11-20 | Новартис Аг | Рекомбинантные самореплицирующиеся полицистронные молекулы рнк |
| CN107266391B (zh) | 2011-10-18 | 2020-04-17 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
| EP2768528A1 (en) | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| EP3290050B1 (en) | 2011-11-03 | 2019-01-02 | Sentinext Therapeutics SDN BHD | Vaccines directed against human enteroviruses |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| EP3485875A1 (en) | 2011-11-04 | 2019-05-22 | Nitto Denko Corporation | Single use system for sterelily producing lipid-nucleic acid particles |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| CN103221064B (zh) | 2011-11-23 | 2014-12-03 | 苏州工业园区唯可达生物科技有限公司 | 抗流感病毒的免疫方法及其组合疫苗 |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| KR20140111272A (ko) | 2011-12-12 | 2014-09-18 | 교와 핫꼬 기린 가부시키가이샤 | 양이온성 지질의 조합을 함유하는 지질 나노 입자 |
| JP6182457B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
| WO2013130161A1 (en) | 2011-12-14 | 2013-09-06 | modeRNA Therapeutics | Methods of responding to a biothreat |
| WO2013090186A1 (en) * | 2011-12-14 | 2013-06-20 | modeRNA Therapeutics | Modified nucleic acids, and acute care uses thereof |
| WO2013087083A1 (en) | 2011-12-15 | 2013-06-20 | Biontech Ag | Particles comprising single stranded rna and double stranded rna for immunomodulation |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| CN104968354A (zh) | 2011-12-21 | 2015-10-07 | 现代治疗公司 | 增加器官或器官外植体的活力或寿命的方法 |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| AU2013231638B2 (en) | 2012-03-16 | 2017-10-12 | Merck Patent Gmbh | Targeting aminoacid lipids |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9717685B2 (en) | 2012-03-26 | 2017-08-01 | President And Fellows Of Harvard College | Lipid-coated nucleic acid nanostructures of defined shape |
| SG11201405542UA (en) | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| AU2013237874B2 (en) | 2012-03-29 | 2018-01-18 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| HK1210479A1 (en) | 2012-04-10 | 2016-04-22 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| HRP20181855T1 (hr) | 2012-06-08 | 2018-12-28 | Nitto Denko Corporation | Lipidi za formulacije namijenjene unosu terapijskog sredstva |
| EP2858679B2 (en) * | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| JP2015524849A (ja) | 2012-08-15 | 2015-08-27 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 神経変性疾患に対するエキソソームに基づく治療法 |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| US20150202153A1 (en) | 2012-10-04 | 2015-07-23 | University Of The Witwatersrand, Johannesburg | Liposomal drug delivery system |
| KR102121086B1 (ko) | 2012-11-01 | 2020-06-09 | 팩터 바이오사이언스 인크. | 세포에서 단백질을 발현시키는 방법들과 생성물들 |
| TW201428101A (zh) | 2012-11-08 | 2014-07-16 | Inviragen Inc | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| TR201809547T4 (tr) | 2012-11-09 | 2018-07-23 | Biontech Rna Pharmaceuticals Gmbh | Hücresel RNA ifadesine yönelik yöntem. |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| WO2014089239A1 (en) | 2012-12-07 | 2014-06-12 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| EP4331620A3 (en) | 2012-12-07 | 2024-12-04 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery |
| WO2014093574A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
| CN109045294A (zh) | 2013-01-10 | 2018-12-21 | 思齐乐 | 流感病毒免疫原性组合物及其应用 |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| BR112015022855A2 (pt) | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| EP2970940B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| KR20150130283A (ko) | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 생체분자 보조제를 갖는 백신 |
| CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| CN105007938A (zh) | 2013-03-15 | 2015-10-28 | 宾夕法尼亚大学理事会 | 流感核酸分子和由其制备的疫苗 |
| US8980864B2 (en) * | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| DK2970948T3 (en) | 2013-03-15 | 2019-04-08 | Glaxosmithkline Biologicals Sa | METHODS OF RNA PURIFICATION |
| WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| ES2803508T3 (es) | 2013-03-28 | 2021-01-27 | Medicago Inc | Producción de partículas similares al virus de la gripe en plantas |
| WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
| WO2014210356A1 (en) | 2013-06-26 | 2014-12-31 | Massachusetts Institute Of Technology | Multi-tailed lipids and uses thereof |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| CA2917348A1 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| JP6620093B2 (ja) | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| US10125172B2 (en) | 2013-07-25 | 2018-11-13 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| WO2015023461A2 (en) | 2013-08-06 | 2015-02-19 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| AU2014337156A1 (en) | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
| ES3032935T3 (en) | 2013-10-22 | 2025-07-29 | Translate Bio Inc | Lipid formulations for delivery of messenger rna |
| EP2883872A1 (en) | 2013-12-16 | 2015-06-17 | Universite De Bordeaux I | Five-membered cyclic biscarbonates bearing amide linkages, their preparation and their uses for the preparation of polyhydroxyurethanes |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| CA2955375A1 (en) | 2014-07-17 | 2016-01-21 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US11191727B2 (en) | 2014-12-31 | 2021-12-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent nanoparticle-based vaccines |
| EP3247363A4 (en) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| WO2016201377A1 (en) | 2015-06-10 | 2016-12-15 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| US11364292B2 (en) * | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) * | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| WO2017015457A1 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US20190008887A1 (en) | 2015-07-30 | 2019-01-10 | ModernaTX Inc. | Multimeric mrna |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017031241A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Rna mapping/fingerprinting |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| WO2017070624A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| EA201891000A1 (ru) | 2015-10-22 | 2018-12-28 | МОДЕРНАТиЭкс, ИНК. | Вакцина против респираторно-синцитиального вируса |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3365009A4 (en) | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| AU2016342045A1 (en) * | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| JP7384512B2 (ja) | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| MA43568A (fr) | 2015-12-17 | 2018-11-14 | Modernatx Inc | Polynucléotides codant pour la méthylmalonyl-coa mutase |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3426775A1 (en) | 2016-03-10 | 2019-01-16 | Novartis AG | Chemically modified messenger rna's |
| US12508308B2 (en) | 2016-05-04 | 2025-12-30 | CureVac SE | Influenza mRNA vaccines |
| JP2019519601A (ja) | 2016-05-18 | 2019-07-11 | モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． | 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| WO2017201328A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| WO2017201317A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| MA45036A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 |
| SI3458083T1 (sl) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
| US11001861B2 (en) | 2016-05-18 | 2021-05-11 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| US12123030B2 (en) | 2016-05-18 | 2024-10-22 | Modernatx, Inc. | Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia |
| EP3458108A4 (en) | 2016-05-18 | 2020-04-22 | ModernaTX, Inc. | POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS |
| WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN109563511A (zh) | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| EP3528827A4 (en) | 2016-10-21 | 2020-11-04 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
| CA3040337A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| CN110402145A (zh) | 2016-10-26 | 2019-11-01 | 莫得纳特斯公司 | 用于增强免疫应答的信使核糖核酸及其使用方法 |
| WO2018081462A1 (en) | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Methods and compositions for rna mapping |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| AU2017357758B2 (en) | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| US20180243225A1 (en) | 2017-01-25 | 2018-08-30 | Modernatx, Inc. | Ebola/marburg vaccines |
| CN109152830B (zh) | 2017-01-27 | 2023-11-03 | 卫理公会医院 | 用于免疫疗法的核/壳结构平台 |
| US20190351040A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Rna cancer vaccines |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| EP3577221A4 (en) | 2017-02-01 | 2020-12-23 | ModernaTX, Inc. | Polynucleotide secondary structure |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018157009A1 (en) | 2017-02-24 | 2018-08-30 | Modernatx, Inc. | Nucleic acid-based therapy of muscular dystrophies |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| WO2018175783A1 (en) | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| WO2018200737A1 (en) | 2017-04-26 | 2018-11-01 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018232355A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna antibodies |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MA49634A (fr) | 2017-07-21 | 2020-05-27 | Modernatx Inc | Arnm modifié codant pour une propionyl-coa-carboxylase et utilisations associées |
| US20200254086A1 (en) | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| SI3703658T1 (sl) | 2017-10-31 | 2022-09-30 | Astrazeneca Ab | Lipidni nanodelci za dostavljanje spremenjene RNA, ki kodira polipeptid VEGF-A |
| US20190192646A1 (en) | 2017-11-03 | 2019-06-27 | Modernatx, Inc. | Salmonella vaccines |
| MA50813A (fr) | 2017-11-21 | 2020-09-30 | Modernatx Inc | Vaccins contre le virus d'epstein-barr |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| AU2019293244B2 (en) | 2018-06-27 | 2026-04-02 | Modernatx, Inc. | Personalized cancer vaccine epitope selection |
| CA3111836A1 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| MA54192A (fr) | 2018-11-07 | 2021-09-15 | Modernatx Inc | Vaccins à arn contre le cancer |
| CN118697900A (zh) | 2019-01-31 | 2024-09-27 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| SG11202110036RA (en) | 2019-03-19 | 2021-10-28 | Arcturus Therapeutics Inc | Method of making lipid-encapsulated rna nanoparticles |
| US20220236253A1 (en) | 2019-05-31 | 2022-07-28 | Modernatx, Inc. | Expanded t cell assay |
| CN114269918A (zh) | 2019-08-14 | 2022-04-01 | 摩登纳特斯有限公司 | 用于纯化体外转录的下游产物的方法 |
| CA3154082A1 (en) | 2019-09-11 | 2021-03-18 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2021055811A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Cap guides and methods of use thereof for rna mapping |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4088281A4 (en) | 2020-01-10 | 2024-02-21 | ModernaTX, Inc. | VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE |
| US20210228707A1 (en) | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| JP2023513073A (ja) | 2020-01-30 | 2023-03-30 | モデルナティエックス インコーポレイテッド | 呼吸器系ウイルス免疫化組成物 |
| CA3169669A1 (en) | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| BR112022015565A2 (pt) | 2020-02-07 | 2022-09-27 | Modernatx Inc | Vacinas de domínio de mrna para sars-cov-2 |
| WO2021211343A1 (en) | 2020-04-13 | 2021-10-21 | Modernatx, Inc. | Zika virus mrna vaccines |
| WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
| EP4149485A4 (en) | 2020-05-15 | 2024-10-23 | ModernaTX, Inc. | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION AND METHODS OF USE THEREOF FOR THE TREATMENT OF COVID-19 |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| EP4153238A4 (en) | 2020-05-21 | 2024-12-18 | ModernaTX, Inc. | METHYLENE BLUE STABILIZED MRNA COMPOSITIONS |
| CA3185855A1 (en) | 2020-06-05 | 2021-12-09 | Modernatx, Inc. | Bacterial strains for dna production |
| MA71659A (fr) | 2020-08-06 | 2025-05-30 | Modernatx, Inc. | Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4217371A1 (en) | 2020-09-25 | 2023-08-02 | ModernaTX, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| KR20230087536A (ko) | 2020-10-12 | 2023-06-16 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 프로세스 |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| WO2022155524A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| JP2024503699A (ja) | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | バリアント株ベースのコロナウイルスワクチン |
| EP4301405A4 (en) | 2021-03-05 | 2025-01-29 | ModernaTX, Inc. | ENTEROVIRAL VACCINES WITH VIRUS-LIKE PARTICLES (VLP) |
| JP2024511346A (ja) | 2021-03-15 | 2024-03-13 | モデルナティエックス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２ ｍｒｎａドメインワクチンの治療的使用 |
| CA3212653A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4313072A1 (en) | 2021-03-26 | 2024-02-07 | ModernaTX, Inc. | Pertussis vaccine |
| WO2022212442A1 (en) | 2021-03-31 | 2022-10-06 | Modernatx, Inc. | Synthesis of trinucleotide and tetranucleotide caps for mrna production |
| JP2024512780A (ja) | 2021-04-01 | 2024-03-19 | モデルナティエックス インコーポレイテッド | 多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法 |
| WO2022212191A1 (en) | 2021-04-01 | 2022-10-06 | Modernatx, Inc. | Mucosal expression of antibody structures and isotypes by mrna |
| WO2022221336A1 (en) | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Respiratory syncytial virus mrna vaccines |
| JP2024514182A (ja) | 2021-04-13 | 2024-03-28 | モデルナティエックス インコーポレイテッド | 呼吸器ウイルス組み合わせワクチン |
| EP4322997A4 (en) | 2021-04-13 | 2025-02-26 | ModernaTX, Inc. | EPSTEIN-BARR VIRUS mRNA VACCINES |
| WO2022221440A1 (en) | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
| WO2022226318A1 (en) | 2021-04-23 | 2022-10-27 | Modernatx, Inc. | Isoquinoline-stabilized lipid nanoparticle formulations |
| EP4326227A1 (en) | 2021-04-23 | 2024-02-28 | ModernaTX, Inc. | Stabilized formulations |
| WO2022232585A1 (en) | 2021-04-29 | 2022-11-03 | Modernatx, Inc. | Lyophilization methods for preparing lipid formulated therapeutics |
| CA3218913A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Immunogenic composition against influenza |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
| EP4355761A1 (en) | 2021-06-14 | 2024-04-24 | ModernaTX, Inc. | Mrna vaccines encoding flexible coronavirus spike proteins |
| US20240293534A1 (en) | 2021-06-14 | 2024-09-05 | Modernatx, Inc. | Coronavirus glycosylation variant vaccines |
| US20240218353A1 (en) | 2021-06-17 | 2024-07-04 | Modernatx, Inc. | Alternative rna purification strategies |
| US20240382581A1 (en) | 2021-07-09 | 2024-11-21 | Modernatx, Inc. | Pan-human coronavirus vaccines |
| US20240358819A1 (en) | 2021-07-09 | 2024-10-31 | Modernatx, Inc. | Pan-human coronavirus domain vaccines |
| WO2023283642A2 (en) | 2021-07-09 | 2023-01-12 | Modernatx, Inc. | Pan-human coronavirus concatemeric vaccines |
| US20250092440A1 (en) | 2021-08-02 | 2025-03-20 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment |
| WO2023018773A1 (en) | 2021-08-11 | 2023-02-16 | Modernatx, Inc. | Lipid nanoparticle formulations and methods of synthesis thereof |
| WO2023019181A1 (en) | 2021-08-11 | 2023-02-16 | Modernatx, Inc. | Sars-cov-2 lipid nanoparticle vaccine formulations |
| EP4384613A1 (en) | 2021-08-13 | 2024-06-19 | ModernaTX, Inc. | Multicolumn chromatography mrna purification |
| WO2023056401A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus |
| WO2023069895A1 (en) | 2021-10-18 | 2023-04-27 | Modernatx, Inc. | Markerless dna production |
| JP2024540917A (ja) | 2021-10-18 | 2024-11-06 | モデルナティエックス インコーポレイテッド | 組み換えタンパク質生産のためのカスタム株 |
| EP4419082A1 (en) | 2021-10-20 | 2024-08-28 | ModernaTX, Inc. | Drug product surrogate solutions |
| EP4423187A1 (en) | 2021-10-26 | 2024-09-04 | Exopolymer, Inc. | Heat stable and/or heat activated biopolymers |
| WO2023081311A1 (en) | 2021-11-05 | 2023-05-11 | Modernatx, Inc. | Methods of purifying dna for gene synthesis |
| WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| US20250360194A1 (en) | 2021-12-08 | 2025-11-27 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
| EP4448777A1 (en) | 2021-12-15 | 2024-10-23 | ModernaTX, Inc. | Determination of encapsulation efficiency of lipid nanoparticles |
| US20250084397A1 (en) | 2022-01-04 | 2025-03-13 | Modernatx, Inc. | Methods of purifying dna for gene synthesis |
| EP4463545A1 (en) | 2022-01-14 | 2024-11-20 | ModernaTX, Inc. | In vitro transcription dna purification and recycling |
| EP4473107A1 (en) | 2022-02-03 | 2024-12-11 | ModernaTX, Inc. | Continuous precipitation for mrna purification |
| EP4475882A1 (en) | 2022-02-09 | 2024-12-18 | ModernaTX, Inc. | Mucosal administration methods and formulations |
| WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
| EP4508242A1 (en) | 2022-04-11 | 2025-02-19 | ModernaTX, Inc. | Detection of mrna purity in a mixture |
| EP4508201A1 (en) | 2022-04-14 | 2025-02-19 | ModernaTX, Inc. | Rna polymerase variants |
| US20250251391A1 (en) | 2022-04-15 | 2025-08-07 | Modernatx, Inc. | Ribosomal engagement potency assay |
| WO2023212696A1 (en) | 2022-04-29 | 2023-11-02 | Modernatx, Inc. | Lyophilized human cytomegalovirus vaccines |
| EP4525830A1 (en) | 2022-05-17 | 2025-03-26 | ModernaTX, Inc. | Preparation of highly concentrated mrna |
-
2015
- 2015-04-23 PL PL21195046.4T patent/PL4023249T3/pl unknown
- 2015-04-23 FI FIEP21191353.8T patent/FI3981437T3/fi active
- 2015-04-23 AU AU2015249553A patent/AU2015249553B2/en not_active Withdrawn - After Issue
- 2015-04-23 LT LTEPPCT/US2015/027400T patent/LT3134131T/lt unknown
- 2015-04-23 PT PT157836065T patent/PT3134131T/pt unknown
- 2015-04-23 FI FIEP21195046.4T patent/FI4023249T3/fi active
- 2015-04-23 SI SI201532048T patent/SI3981437T1/sl unknown
- 2015-04-23 EP EP21191353.8A patent/EP3981437B1/en active Active
- 2015-04-23 EP EP15783606.5A patent/EP3134131B1/en active Active
- 2015-04-23 LT LTEP21195046.4T patent/LT4023249T/lt unknown
- 2015-04-23 SM SM20250052T patent/SMT202500052T1/it unknown
- 2015-04-23 RU RU2021109685A patent/RU2021109685A/ru unknown
- 2015-04-23 WO PCT/US2015/027400 patent/WO2015164674A1/en not_active Ceased
- 2015-04-23 PL PL21191353.8T patent/PL3981437T3/pl unknown
- 2015-04-23 EP EP24204789.2A patent/EP4501318A3/en active Pending
- 2015-04-23 RS RS20250021A patent/RS66380B1/sr unknown
- 2015-04-23 PT PT211913538T patent/PT3981437T/pt unknown
- 2015-04-23 HU HUE21195046A patent/HUE069802T2/hu unknown
- 2015-04-23 RU RU2016145597A patent/RU2746406C2/ru active
- 2015-04-23 HU HUE21191353A patent/HUE069770T2/hu unknown
- 2015-04-23 PL PL15783606T patent/PL3134131T3/pl unknown
- 2015-04-23 SM SM20220158T patent/SMT202200158T1/it unknown
- 2015-04-23 CA CA2946751A patent/CA2946751A1/en active Pending
- 2015-04-23 ES ES21195046T patent/ES3003986T3/es active Active
- 2015-04-23 EP EP21195046.4A patent/EP4023249B1/en active Active
- 2015-04-23 RS RS20220289A patent/RS63050B1/sr unknown
- 2015-04-23 HR HRP20241732TT patent/HRP20241732T1/hr unknown
- 2015-04-23 HU HUE15783606A patent/HUE057800T2/hu unknown
- 2015-04-23 CN CN201580033861.2A patent/CN106659803A/zh active Pending
- 2015-04-23 MA MA58292A patent/MA58292B1/fr unknown
- 2015-04-23 DK DK21195046.4T patent/DK4023249T3/da active
- 2015-04-23 HR HRP20241733TT patent/HRP20241733T1/hr unknown
- 2015-04-23 SG SG11201608798YA patent/SG11201608798YA/en unknown
- 2015-04-23 ES ES21191353T patent/ES3009962T3/es active Active
- 2015-04-23 SI SI201531776T patent/SI3134131T1/sl unknown
- 2015-04-23 DK DK15783606.5T patent/DK3134131T3/da active
- 2015-04-23 SM SM20250053T patent/SMT202500053T1/it unknown
- 2015-04-23 HR HRP20220070TT patent/HRP20220070T1/hr unknown
- 2015-04-23 JP JP2017507919A patent/JP6881813B2/ja active Active
- 2015-04-23 MA MA59052A patent/MA59052B1/fr unknown
- 2015-04-23 LT LTEP21191353.8T patent/LT3981437T/lt unknown
- 2015-04-23 RS RS20250020A patent/RS66388B1/sr unknown
- 2015-04-23 SI SI201532049T patent/SI4023249T1/sl unknown
- 2015-04-23 ES ES15783606T patent/ES2909180T3/es active Active
- 2015-04-23 PT PT211950464T patent/PT4023249T/pt unknown
- 2015-04-23 DK DK21191353.8T patent/DK3981437T3/da active
- 2015-04-23 SG SG10201912038TA patent/SG10201912038TA/en unknown
- 2015-04-23 CA CA3177878A patent/CA3177878A1/en active Pending
-
2016
- 2016-04-01 US US15/089,050 patent/US10022435B2/en active Active
- 2016-04-05 US US15/091,123 patent/US9872900B2/en active Active
-
2018
- 2018-07-16 US US16/036,318 patent/US20190008948A1/en not_active Abandoned
- 2018-07-27 US US16/048,154 patent/US10709779B2/en active Active
- 2018-09-27 US US16/144,394 patent/US20190015501A1/en not_active Abandoned
-
2021
- 2021-02-05 JP JP2021017295A patent/JP7504464B2/ja active Active
- 2021-03-17 US US17/204,801 patent/US20210220467A1/en not_active Abandoned
- 2021-05-28 AU AU2021203492A patent/AU2021203492A1/en not_active Abandoned
-
2022
- 2022-02-28 US US17/683,171 patent/US20240398927A9/en not_active Abandoned
- 2022-03-18 CY CY20221100220T patent/CY1125084T1/el unknown
-
2024
- 2024-02-26 JP JP2024026489A patent/JP2024071384A/ja active Pending
- 2024-08-12 US US18/801,174 patent/US12329812B2/en active Active
- 2024-08-12 US US18/801,071 patent/US20240408191A1/en not_active Abandoned
- 2024-08-12 US US18/801,143 patent/US12274743B2/en active Active
- 2024-11-26 AU AU2024266879A patent/AU2024266879A1/en active Pending
-
2025
- 2025-04-24 US US19/188,713 patent/US20260091104A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3981437T3 (fi) | Nukleiinihapporokotteita | |
| RU2020116571A (ru) | N4-гидроксицитидин и производные и связанные с этим противовирусные применения | |
| ZA202106848B (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| JP2018537521A5 (enExample) | ||
| WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| UA114351C2 (uk) | Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування | |
| JP2009539965A5 (enExample) | ||
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| EA201590862A1 (ru) | Фармацевтические композиции | |
| ATE412667T1 (de) | Langwirkende fusionspeptidinhibitoren gegen hiv- infektion | |
| WO2012174312A3 (en) | Benzimidazole derivatives as antiviral agents | |
| EA201890196A1 (ru) | Композиция для устранения заложенности носа, обладающая противовирусным действием | |
| CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
| BRPI0921424A2 (pt) | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. | |
| PH12019550039A1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| EA200602289A1 (ru) | Применение иматиниба для лечения нарушений работы печени и вирусных инфекций | |
| WO2013162350A3 (en) | Circular antiviral rna | |
| Ilina et al. | Inhibitors of HIV‐1 reverse transcriptase | |
| WO2009152519A3 (en) | Novel antiviral peptides against influenza virus | |
| WO2004052905A3 (en) | Antiviral nucleoside derivatives | |
| DK1765370T3 (da) | Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS | |
| WO2006045616A3 (en) | β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | |
| WO2014124092A3 (en) | Lamivudine crystalline salts | |
| BR112019017855A8 (pt) | Compostos, composição farmacêutica compreendendo os ditos compostos, usos dos mesmos para tratar o vírus da hepatite b e o vírus da imunodeficiência humana e processo para a preparação dos ditos compostos |